These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 32344632)

  • 1. Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment.
    Kotur N; Lazic J; Ristivojevic B; Stankovic B; Gasic V; Dokmanovic L; Krstovski N; Milosevic G; Janic D; Zukic B; Pavlovic S
    Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32344632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.
    Radtke S; Zolk O; Renner B; Paulides M; Zimmermann M; Möricke A; Stanulla M; Schrappe M; Langer T
    Blood; 2013 Jun; 121(26):5145-53. PubMed ID: 23652803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of genetic polymorphisms in the thymidylate synthase (TYMS) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.
    Oosterom N; Berrevoets M; den Hoed MAH; Zolk O; Hoerning S; Pluijm SMF; Pieters R; de Jonge R; Tissing WJE; van den Heuvel-Eibrink MM; Heil SG
    Pharmacogenet Genomics; 2018 Oct; 28(10):223-229. PubMed ID: 30222710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.
    Faganel Kotnik B; Grabnar I; Bohanec Grabar P; Dolžan V; Jazbec J
    Eur J Clin Pharmacol; 2011 Oct; 67(10):993-1006. PubMed ID: 21509569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia.
    Erčulj N; Kotnik BF; Debeljak M; Jazbec J; Dolžan V
    Leuk Lymphoma; 2012 Jun; 53(6):1096-104. PubMed ID: 22074251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate pharmacogenetics in Uruguayan adults with hematological malignant diseases.
    Giletti A; Vital M; Lorenzo M; Cardozo P; Borelli G; Gabus R; Martínez L; Díaz L; Assar R; Rodriguez MN; Esperón P
    Eur J Pharm Sci; 2017 Nov; 109():480-485. PubMed ID: 28887233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
    Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
    Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia.
    Zgheib NK; Akra-Ismail M; Aridi C; Mahfouz R; Abboud MR; Solh H; Muwakkit SA
    Pharmacogenet Genomics; 2014 Aug; 24(8):387-96. PubMed ID: 25007187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
    Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
    Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia.
    Salazar J; Altés A; del Río E; Estella J; Rives S; Tasso M; Navajas A; Molina J; Villa M; Vivanco JL; Torrent M; Baiget M; Badell I
    Pharmacogenomics J; 2012 Oct; 12(5):379-85. PubMed ID: 21747412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of variants in folate metabolism genes on 6-mercaptopurine induced toxicity during treatment for childhood acute lymphocytic leukemia.
    Milosevic G; Kotur N; Lazic J; Krstovski N; Stankovic B; Zukic B; Janic D; Jurisic V; Pavlovic S; Dokmanovic L
    J BUON; 2019; 24(5):2075-2083. PubMed ID: 31786878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional variants of gene encoding folate metabolizing enzyme and methotrexate-related toxicity in children with acute lymphoblastic leukemia.
    Kałużna E; Strauss E; Zając-Spychała O; Gowin E; Świątek-Kościelna B; Nowak J; Fichna M; Mańkowski P; Januszkiewicz-Lewandowska D
    Eur J Pharmacol; 2015 Dec; 769():93-9. PubMed ID: 26528799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of plasma methotrexate level and MTHFR genotype in Korean paediatric patients with acute lymphoblastic leukaemia.
    Chae H; Kim M; Choi SH; Kim SK; Lee JW; Chung NG; Cho B; Kim Y
    J Chemother; 2020 Sep; 32(5):251-259. PubMed ID: 32431230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: a meta-analysis.
    He HR; Liu P; He GH; Dong WH; Wang MY; Dong YL; Lu J
    Leuk Lymphoma; 2014 Dec; 55(12):2793-800. PubMed ID: 24597986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies.
    Suthandiram S; Gan GG; Zain SM; Bee PC; Lian LH; Chang KM; Ong TC; Mohamed Z
    Pharmacogenomics; 2014 Aug; 15(11):1479-94. PubMed ID: 25303299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese population.
    Liu SG; Li ZG; Cui L; Gao C; Li WJ; Zhao XX
    Leuk Lymphoma; 2011 Jun; 52(6):1030-40. PubMed ID: 21534867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma.
    Kantar M; Kosova B; Cetingul N; Gumus S; Toroslu E; Zafer N; Topcuoglu N; Aksoylar S; Cinar M; Tetik A; Eroglu Z
    Leuk Lymphoma; 2009 Jun; 50(6):912-7. PubMed ID: 19391036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folate pathway genetic polymorphisms modulate methotrexate-induced toxicity in childhood acute lymphoblastic leukemia.
    Yousef AM; Farhad R; Alshamaseen D; Alsheikh A; Zawiah M; Kadi T
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):755-762. PubMed ID: 30684021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia.
    Iparraguirre L; Gutierrez-Camino A; Umerez M; Martin-Guerrero I; Astigarraga I; Navajas A; Sastre A; Garcia de Andoin N; Garcia-Orad A
    Pharmacogenet Genomics; 2016 Nov; 26(11):517-525. PubMed ID: 27649261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment.
    Rudin S; Marable M; Huang RS
    Genomics Proteomics Bioinformatics; 2017 Apr; 15(2):82-93. PubMed ID: 28391009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.